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Throughout the past twenty years, humankind had its fair share of challenges with viral 
epidemics. In late December 2019, a zoonotic member of the coronaviruses, was re-
sponsible for the COVID-19 outbreak of viral pneumonia in Wuhan, China. As a world-
wide crisis, meanwhile a conclusive prevention or therapy has yet to be discovered, the 
death toll of COVID-19 has exceeded 278000 by May 11th 2020. Alike other members 
of Coronavirus family such as MERS and SARS-CoV-1, SARS-CoV-2 provokes influ-
enza-like syndrome which might further progress to severe state of acute respiratory 
disease in some patients. Comparably, in 2009 the H1N1 influenza outbreak affected 
countless people by manifestations of respiratory system involvement. Additionally, 
Ebolavirus, as a member of Filoviridae family, had also made a global catastrophe by 
causing hemorrhagic diseases in the past twenty years.  The unknown intrinsic nature 
of SARS-CoV-2, as a great missing piece of this pandemic puzzle, has had physicians 
to empirically test the possibly efficacious agents of the former viral epidemics on the 
COVID-19 cases. Here, the current knowledge in SARS-CoV-2clinical features, trans-
missibility, and pathogenicity are all summed up as against the other emerging viruses 
in the last two decades, and the data crucially required for a better management of the 
illness has been spotlighted.
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A new fatal infection referred to as severe acute respiratory syn-
drome (SARS) was identified as a major threat to public health 
at the start of this century [1]. Ensuingly, near a decade after the 
original SARS report, occurrences of another abnormal respi-
ratory disorder triggered worldwide alarm in 2012. The illness 
was known as Middle East Respiratory Syndrome (MERS) and 
became much more deadly than SARS [2]. Both the causal vi-
ruses of the SARS and MERS outbreaks were members of the 
Coronavirus family [3]. Big groups of influenza-like syndrome 
cases were identified in Wuhan province, China at the end of 
December 2019 [4]. History has now recurred with the advent 
of a new Chinese outbreak at the end of 2019. A novel corona-
virus (SARS-CoV-2) has been described as the etiologic factor 
for this respiratory disorder named COVID-19. In total, SARS, 
MERS and COVID-19 are triggered by newly identified coro-
naviruses that induce flu-like disease, albeit with a tendentially 
more serious clinical result. After near 4 months of COVID-19 
pandemic, the number of people afflicted with COVID-19 has 
exceeded 4 million, and more than 278000 cases have died up 
until May 11th, 2020.  The 2009 H1N1 flu pandemic, much like 
the clinical manifestation and spreading of COVID-19, affect-
ed individuals, involving their respiratory tracts, through drop-
lets and contacts between humans [5]. In addition, Ebola Virus 
Disease (EVD), another viral epidemic that a family member 
of Filoviridae first gave birth to in 1976, became the greatest 
epidemic in 2013 leading to hemorrhagic fever and fatality 
in countless individuals [6]. In the present review, we seek to 
evaluate our present knowledge about the 21th century viral 
outbreaks of SARS-CoV-1, SARS-CoV-2, MERS-CoV, H1N1 
influenza, and Ebola in terms of epidemiology, pathogenesis, 
and clinical futures in order to identify the characteristics of the 
enigmatic novel coronavirus.
SARS-CoV-1 
Coronaviruses, a category of viruses, are the reason for a large 
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or group of symptoms shown to be specific. While the histo-
ry of being febrile is the most commonly recorded feature, it 
can be missing from initial speculation. Coughing, shortness 
of breath, and diarrhea may occur in the first 7 days of the dis-
ease, but in fact are noted most frequently in the second week 
[8]. Up to 70 percent of cases at this point experience diarrhea, 
which has been identified as watery and abundant without mu-
cus or blood [9]. Extreme cases aggravate by the end of the 
second week, which quickly develop progressive respiratory 
problems, while around 20% of them might need intensive 
care [10]. Laboratory features comprise raised creatine kinase 
and alanine aminotransferase (AAT) (30%), thrombocytopenia 
(45%), and lymphopenia (70%) [11]. The accessible pathology 
proportion of all common colds in both children and adults. 
Four coronaviruses that are specific to humans, comprising 
229E and NL63 as alpha coronaviruses and HKU1 and OC43 
as beta coronaviruses are widespread and usually provoke 
common cold presentations in human [7]. The SARS, as a 
member of coronavirus family, is thought to have moved from 
animal hosts to human hosts in livestock markets of certain 
cities in Guangdong province in southern China in mid-No-
vember 2002 [7]. SARS-CoV-1 causing SARS has a particular 
pathogenesis, since it induces infections of the upper and lower 
respiratory tract. Patients first experience prodromal flu-like 
manifestations with symptoms such as rigors, headache, mal-
aise, and fever. But there hasn’t been any particular symptom 
A Comparative Review on the Major Viral Pandemics
Table.1: Epidemiological comparison of SARS-CoV1, SARS-CoV2, MERS-CoV, Influenza H1N1, and Ebola viral outbreaks.
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details for SARS-CoV-1 infection have been mainly collected 
from autopsy procedures. The macroscopic alterations in fatal 
patients of SARS-CoV-1 were edematous pulmonary tissues 
with elevated gross weights and numerous congestive zones, 
lymph node enlargement in abdominal cavity and the hilum of 
lung, as well as a decrease in spleen’s weight and size [1, 12]. 
Significant amounts of SARS-CoV-1 genomic sequences and 
particles have been found inside lymphoid tissues, circulating 
monocytes  and lymphocytes, as well as within brain neurons, 
renal distal tubular epithelial cells, mucosa of intestine, airway 
epithelium, and tissue-resident macrophages of specific organs 
[13]. Co-location of cellular cytokeratin and SARS-CoV-1 
RNA inside pulmonary tissue was demonstrated by immuno-
fluorescence in situ hybridization, suggesting that pulmonary 
cells have become infected. In addition, SARS-CoV-1 can 
sometimes be found in the alveolar macrophages within lungs 
[14]. Large-scale lung injury in SARS-CoV-1-infected cases 
tends to be correlated with elevated initial viral load, increased 
plasma pro-inflammatory chemokines and cytokines, high lev-
els of neutrophil, macrophage, and monocyte infiltration in the 
lungs [15, 16]. Research on alterations in inflammatory  profiles 
in the course of SARS-CoV-1 infection, have shown elevated 
levels of circulating cytokines, such as interleukin types of 6 
and 8 as well as C-X-C motif chemokine and TNF-alpha which 
possibly will lead to adverse prognosis in SARS-CoV-1 [17]. 
Moreover, high serum levels IL-1, IL-12, TGF-β, IFN-γ, and 
CCL2 were observed in SARS cases with serious disease rel-
ative to uncomplicated SARS cases. [14, 18, 19]. The magni-
tude of the illness is oftentimes a significant indirect element in 
the capacity of the virus to transmit. Since coronaviruses have 
RNA-dependent polymerases that are susceptible to errors, 
recombination events and mutations often take place, which 
results in quasi-species variability; something that is strongly 
related to adaptive evolution and disease-causing capacity [20]. 
SARS CoV-2
The COVID-19 outbreak emerged in the winter on a local sea-
food market, in circumstances comparable to SARS’s. In fact 
two thirds of the initial 41 reported cases have been listed as 
having ties to the Huanan Seafood Wholesale Market [21]. On 
11th march 2020 WHO declared the outbreak of COVID-19, a 
pandemic [22].  Almost all nations have been challenged with 
the disease, because of which overall more than 4 million peo-
ple have been afflicted and 278892 cases have died worldwide 
until May 11th, 2020 (See Table.1). Roughly after one month 
from the start of the SARS-CoV-2 outbreak, many clinical and 
virological elements of the COVID-19 are still under evalua-
tion. The SARS-CoV-2 genome was sequenced very early in 
the course of the outbreak [23]. This provided for the acceler-
ated production of real-time RT-PCR diagnostic tests uniquely 
for SARS-CoV-2at the point of patient treatment [24]. In fact 
the causative virus of 2019 outbreak was called Severe Acute 
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), regard-
ing its genomic resemblance to the SARS virus [25]. The ge-
netic sequencing study divulged that the novel corona viruses 
belong to the group beta-coronavirus, with MERS-CoV nucle-
otide identification at 51.8 percent and SARS-CoV nucleotide 
identification at 79.0 percent [26]. In addition, nCoV-2019 has 
been recorded to be 96 percent similar to a bat coronavirus in 
terms of the entire genetic content [27]. Reportedly, SARS-CoV-
2uses the same cell entry receptor, ACE2, to infect human hosts 
as SARS-CoV [28], therefore the clinical overlap between the 
two viruses may be anticipated especially in extreme cases. Of 
note, there are certain evidence that suggest SARS-CoV-2infec-
tion has had a clustering onset which tends to impact elderly 
people with comorbidity and may contribute to serious respi-
ratory symptoms along with other acute organ injuries [29, 
30]. It is now very obvious that an effective human-to-human 
transmission exists and it’s indeed a requisite for the exten-
sive SARS-CoV-2distribution [21]. The main clinical signs of 
SARS-CoV-2infection at the prodromal level include fatigue, 
dyspnea, dry cough, and nausea [29, 31, 32]. Numerous cases 
have developed lymphopenia as well [33]. The majority of doc-
umented patients, asymptomatic ones included, were presented 
with abnormal chest CT findings such as ground glass opacity or 
consolidation [34]. Early concentrations of, IL-1, IL-7, IL-8, IL-
9, IL-10, VEGF, TNF-α, PDGF, IFNγ, GMCSF, GCSF in plas-
ma were greater among SARS-CoV-2cases as against healthy 
controls. Furthermore, ICU-admitted cases demonstrated greater 
levels of TNF-α, GSCF, IL-10, IL-7, and IL-2 in plasma, com-
pared to non-ICU-admitted cases [35]. Similar to SARS-CoV-1, 
respiratory droplets can transfer the novel coronavirus direct-
ly from one person to another, while evolving data indicates it 
might even be spread by touch and fomites. In addition, it was 
reported that the asymptomatic incubation period for people af-
flicted with SARS-CoV-2varied from 1 to 14 days, longer than 
that for SARS-CoV-1. However it stays unclear whether asymp-
tomatic individuals have sufficiently high viral load to spread 
the viral particles, great focus should be given to minimizing 
associated risks [36]. The basic reproduction number, which is 
normally signified by R0, is a very critical threshold quantity 
correlated with viral transmissibility. The epidemiologic concept 
of R0 is defined as the total number of people getting the dis-
ease from one infectious individual [37]. This refers explicitly 
to a group of non-vaccinated individuals that have earlier been 
healthy. There are three possibilities for the possible propagation 
or regression of a disease, based on its R0 value: 1. If R0 is big-
ger than 1, number of cases may rise exponentially and trigger 
an outbreak or even a pandemic. 2. If R0 is equal to 1, the disease 
will remain alive, but there will be no epidemic. 3. If R0 is less 
than 1, every current infection can cause less than 1 new infec-
tion; in this scenario, the number of cases will decrease and the 
illness will ultimately vanish(37). Based on what we’ve learnt 
by now, the estimated R0 value for SARS-CoV-2is substantial-
ly greater than 1[38]. Sanche S. and others, in the early stages 
of the epidemic, calculated the mean R0 for SARS-CoV-2to be 
5.7 [39], greater than those of MERS-CoV and SARS-CoV-1.
(See Table.1) In SARS-CoV-2transmission, such as those in 
MERS-CoV and SARS-CoV-1, super-spreading incidents were 
involved, but their relative significance has been still uncertain 
and the super-spreaders have been challenging to map.
MERS-CoV 
On 13th June 2012 the first MERS-CoV patients in Saudi Ara-
bia, particularly Jeddah, were announced [40]; following this 
outbreak, coronavirus continued to propagate abroad to multi-
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by a mixture of endogenous and exogenous apoptotic pathways 
[48]. Besides, it has been stated that MERS-CoV could cause 
apoptosis of the lung and kidney cells [49].  Of interest, MERS-
CoV has not changed substantially since it first emerged, which 
may be attributed to the fact that the specific cellular receptor 
(CD26) used by MERS-CoV is rather exclusive, meaning that 
the virus has a quite restricted ability to mutate without sacri-
ficing fitness. Previous experiments, on the other hand, have 
shown that SARS-CoV-1 has evolved during the 2002 to 2004 
outbreak to a better binding to its cellular receptor, and a more 
extensive replication in human cells, thereby amplifying viru-
lence [50]. 
Influenza H1N1 
Three big influenza pandemics happened in the last century: 
1918 (H1N1), 1957 (H2N2) and 1968 (H3N2). The most se-
vere influenza pandemic in modern times remains the 1918 
Spanish flu, which infected more than 50 million people 
around the globe [51]. The influenza pandemic of 2009 that 
started in both the U.S. and Mexico was caused by a novel 
swine influenza strain, (H1N1). Many incidents have happened 
for young adults with nearly 60 percent of recorded cases in the 
United States having happened for individuals 18 years of age 
or younger [52]. The explanation for the rise in attack rates in 
younger individuals is not fully clear, although it has been re-
ported that adults, particularly those born since 1957, have low 
levels of cross-reaction neutralizing antibodies, possibly due 
to repetitive exposures to seasonal H1N1 viruses [53]. Reverse 
transcriptase PCR was considered as the standard procedure for 
the detection and confirmation of influenza A infections during 
pandemic 2009. Approved PCR tests for hospital laboratories 
indicate that the specimen is positive for influenza A but nega-
tive for seasonal H3 and H1 viruses [54]. The clinical features 
in patients diagnosed with the 2009 influenza A pandemic virus 
were close to the normal influenza manifestations which involve 
myalgia, chills, rhinorrhea, sore throat, headache, cough, and 
ple American, European, African, and Asian countries. In the 
course of this outbreak, the majority of patients were in fact 
reported in Middle Eastern nations; including countries with-
in the Gulf, along with Egypt, Palestine, Lebanon, Syria, and 
Jordan. [41].  MERS-CoV’s mean incubation period is 5 to 7 
days but a range of 2 to 14 days has also been recorded [42]. 
The whole clinical gamut of the disease varies from severe 
multi-organ failure disease, moderate disease, to completely 
asymptomatic. Clinical manifestations might include dyspnea, 
coughing, fatigue, myalgia, rigors, fever, and chills in a symp-
tomatic case. Gastrointestinal presentations such as abdominal 
pain, nausea, and emesis, can occur either as a separate main 
complaint or as a part of the upper respiratory syndrome. It 
should be noted that at the time of presentation pneumonia is 
normal(2). Extreme infection takes place particularly in older 
patients with comorbid conditions, presenting with shock, se-
vere renal, and respiratory failure. The average gross fatality 
rate is 35 percent and 20 percent in primary cases and second-
ary cases respectively [43]. Pathophysiological modifications 
induced by MERS-CoV actually depend on the small numbers 
of biopsy and autopsy procedures. MERS-CoV infection tar-
gets specific cells in the lung which are bronchial submucosal 
cells, multinucleated epithelial cells and pneumocytes [44]. In 
terms of ultrastructure, viral particles have been discovered in 
renal epithelial cells and skeletal muscles infiltrated macro-
phages, as well as pulmonary macrophages and pneumocytes. 
The entrance receptor of MERS-CoV, Dipeptidyl peptidase-4 
(DPP4),  has been commonly distributed on the surface of ep-
ithelial cells in the prostate, liver, small intestine, alveoli, kid-
neys, and activated leukocytes [45, 46], Consequently, MERS-
CoV has been shown to be capable of infecting multiple human 
immune cells, considering T-type lymphocytic cells, macro-
phages, and dendritic cells [47]. Robust and continuous devel-
opment of pro-inflammatory chemokines and cytokines results 
in MERS-CoV infections of macrophages and dendritic cells. 
MERS-CoV T-cell infections contribute to apoptosis induced 
A Comparative Review on the Major Viral Pandemics
Figure.1 Mortality rate comparison of COVID-19, SARS, MERS, Influenza H1N1, and 
Ebola viral outbreaks.
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fever [53]. Around one in 10 patients diagnosed with the 2009 
influenza A(H1N1) pandemic virus needed hospitalization. 
The overwhelming majority of patients who were admitted had 
chronic disorders such as diabetes, asthma, neurological and 
respiratory disorders, and pregnancy [55]. Thrombocytopenia, 
anemia, and Leukopenia, follow the above-mentioned signs 
and symptoms in approximately 20–30 percent of cases [56]. 
The trachea and main bronchi have demonstrated necrosis and 
desquamation of infected mucosal epithelium and edema along 
with mixed inflammatory penetration in the underlying sub-
mucosa, in a pathological view of infected cases [52, 57]. The 
glands in certain airways display depletion of contaminated 
goblet cells and underlying submucosal necrosis. In such cases 
the lung parenchyma has demonstrated alterations associated 
with the various phases of diffuse alveolar injury [57]. Infected 
pneumocytes have demonstrated reactive modifications, which 
can desquamate into alveolar spaces which are observed in tan-
dem with infected inter-alveolar macrophages (58). Erythroid 
phagocytosis and Intra-alveolar hemorrhage were also report-
ed. When mortality occurs weeks after the start of symptoms, a 
large distribution of fibroblasts can be seen as well [59]. 
Ebola 
Twenty-four outbreaks of Ebola virus disease (EVD) were 
confirmed between 1976 and 2014, mainly provoked by Zaire 
Ebola virus (ZEBOV) in Equatorial Africa [60]. As shown in 
figure 1 most epidemics were small, but the virus caught the 
world’s attention due to mortality levels as high as 90 percent 
as well as the horrific way it kills [61]. The EVD epidemic in 
West Africa in 2014 induced by ZEBOV is the deadliest, lon-
gest, most large-scale, and most complicated in history. Ebola 
is a public health threat as it can be transmitted fairly quickly, 
particularly in a hospital environment where adequate protec-
tive measures are not taken, and it is almost always lethal ((6). 
EVD may be spread between humans by close interaction with 
body fluids from the infected individuals or fomites. Despite 
aerosol infection has been demonstrated in experimental  mod-
els in monkeys, it has not been clinically documented [62]. One 
reason behind the fact that Ebola is so deadly is that its signs 
differ and indeed manifest rapidly, but at the same time the pre-
sentations are so close to those of other viruses that hemorrhag-
ic fever is not easily detected [63].  Most research have record-
ed that the incubation period ranges from six days to ten days 
for percutaneous and touch exposure respectively [64]. Step I 
of the disease, which can be described as transmitting EBOV 
from animals bearing the virus to humans, typically by minor 
skin lesions.  During Ebola outbreaks same specific concepts 
refer to human-to-human transmission. Phase II is described as 
an early symptomatic stage (usually 4 to 10 days) where signs 
of viral illness emerge and slowly develop into more advanced 
manifestations of the disease. Eventually, phase III is severe 
Ebola virus fever, with hemorrhagic presentations, deficient 
immune system, and end-organ failure [64, 65]. Since reaching 
the body via cracks in the skin, mucous membranes, or paren-
terally, the Ebola virus infects several specific kinds of cells. 
Dendrite cells and macrophage have been usually the first ones 
to be infected; filoviruses quickly multiply within these com-
mon sentinel cells, inducing their necrosis and releasing vast 
amounts of newly created viral particles into extracellular fluid 
[66]. Inhibition of interferon-type l responses which is caused 
by virus, supports the rapid systemic spread. Affected animal 
necropsies have demonstrated that certain kinds of cells (except 
neurons and lymphocytes) can be affected, including adrenal ep-
ithelial cells and cortical cells, as well as hepatocytes, fibroblasts, 
and endothelial cells [67]. Clinical manifestations generally start 
with abrupt flu-like presentations such as rapidly advancing fe-
ver, muscle ache, and headache, which are shortly accompanied 
with hematemesis, Hematochezia, rashes on the body, conjunc-
tivitis, dysphasia (having difficulty swallowing), erythematous 
mucus of the oral cavity, back pain, arthralgia (neurologic pain 
of joints), abdominal pain, malaise, anorexia (loss of appetite), 
nausea and vomiting [6, 65]. Usually, several days later, between 
5 to 7 days after the first presentations patients will start bleeding 
from the mouth, nose, or eyes. A hemorrhagic rash can appear 
across the body, which often bleeds [68]. Possible laboratory 
indicators of Ebola virus disease include a decreased platelet 
count; a primarily reduced white blood cell count succeeded 
by an elevated white blood cell count; increased levels of the 
liver enzymes; and dysfunctions in blood coagulation such as a 
bleeding time, partial thromboplastin time, and prolonged pro-
thrombin time which usually happen in accordance with dissem-
inated intravascular coagulation (DIC)[69]. EVD detection is 
verified by virus isolation and finding antibodies for the virus in 
an individual’s blood. The detection of the virus by cell culture, 
polymerase chain reaction (PCR), and enzyme-linked immuno-
sorbent assay (ELISA) are all means which are best put into use 
in the initial stages of the illness, and also in the detection of 
virus in human remains [70]. The most effective identification 
of anti-viral antibodies occurs in the latter phases of the illness 
and among those that survive. IgG and IgM antibodies can be 
detected 6-18  days and 2 days after the onset of the symptoms 
respectively [71]. Like the other viral disease described earlier, 
data indicates that viral load, confusion, coma, chest pain, and 
age are correlated with the EVD prognosis, in which viral load 
can be one of the most prominent factors for the survival from 
Ebola [72].
Conclusion
The thoroughly detailed lessons learnt from the outbreaks of 
SARS-CoV-1, MERS-CoV, Influenza H1N1, and Ebola include 
useful observations and perspectives into how to battle the 
SARS-CoV-2 pandemic. Drugs that prevent viral transmission 
may reduce the immediate cytopathic impact of coronavirus, and 
therapies that suppress inflammatory responses of the host, pref-
erably only in the respiratory tract, minimize immunopatholo-
gy caused by the viruses. We conclude that the most efficacious 
clinical approach for more severe human coronavirus infections 
will be a mixture of these therapies. Although, we must bear 
in mind that no effective antiviral therapy is currently accessi-
ble for SARS, MERS, and SARS-CoV-2, and thus more work 
into the pathogenesis of human coronavirus infection is indeed 
necessary in order to establish appropriate therapeutic targets. 
Furthermore, since anti-coronaviral medicines and vaccinations 
are still under evaluation, the fear has an undeniable role in 
the social and economic effects of the outbreak of SARS-CoV. 
Therefore, it will be necessary to educate the communities and 
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to reinforce public trust. Providing that the spread of the virus 
from one human to another can be significantly and reliably 
disrupted (R < 1), it is highly probable that the disease can be 
in fact managed and perhaps even eradicated.
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